Castration-resistant prostate cancer: Potential targets and therapies

Aijaz Parray, Hifzur R. Siddique, Sanjeev Nanda, Badrinath R. Konety, Mohammad Saleem

Research output: Contribution to journalReview article

10 Scopus citations

Abstract

The treatment landscape for patients with castration-resistant prostate cancer (CRPC) is undergoing significant changes with the advent of new therapies and multidisciplinary efforts by scientists and clinicians. As activation of multiple molecular pathways in the neoplastic prostate makes it impossible for single-target drugs to be completely effective in treating CRPC, this has led to combination therapy strategy, where several molecules involved in tumor growth and disease progression are targeted by a therapeutic regimen. In the present review, we provide an update on the molecular pathways that play an important role in the pathogenesis of CRPC and discuss the current wave of new treatments to combat this lethal disease.

Original languageEnglish (US)
Pages (from-to)267-276
Number of pages10
JournalBiologics: Targets and Therapy
Volume6
DOIs
StatePublished - Oct 2 2012

    Fingerprint

Keywords

  • CRPC
  • Chemoresistance
  • Molecular pathways
  • Neoplastic prostate

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Oncology
  • Gastroenterology
  • Pharmacology (medical)

Cite this

Parray, A., Siddique, H. R., Nanda, S., Konety, B. R., & Saleem, M. (2012). Castration-resistant prostate cancer: Potential targets and therapies. Biologics: Targets and Therapy, 6, 267-276. https://doi.org/10.2147/BTT.S23954